85.7% of participants were located to “A+” in AD according to the SUVR cut‐off value, and 14.3% were free of Aβ pathology, indicating Aβ and tau were partially independently associated with the AD diagnostic group. The gene discussed is MAPT; the disease is Alzheimer disease.